Estados Unidos · Plataformas y datos · MarketBeat
Ultragenyx Pharmaceutical Targets 2027 Profitability After Deep Cuts and Gene Therapy Launches

Resumen detallado
Ultragenyx Pharmaceutical (NASDAQ:RARE) expects to reach profitability in 2027 as it cuts spending, expands sales of existing rare-disease treatments and launches two gene therapies, executives said at the UBS Global Biopharma Conference. CEO Emil Kakkis said the company is heading toward $1 billio
MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.marketbeat.com)


